Global fluorescein angiography market to grow considerably by 2030

News
Article

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

©ABC Vector – stock.adobe.com

Image credit: ©ABC Vector – stock.adobe.com

Imaging is a powerful tool for ophthalmologists as they diagnosis and treat patients with vision threatening conditions. Fluorescein angiography, fluorescent angiography, or fundus fluorescein angiography is one such tool, which uses a fluorescent dye and a specialized camera to examine the retina and choroid's blood flow.

The global market for fluorescein angiography is growing due to increasing prevalence of eye diseases, desire for early diagnosis, and government efforts to increase public awareness and reduce the number of those affected by blindness.

According to Straits Research, "The global fluorescein angiography market size was valued at USD 498.8 million in 2021 and is projected to reach USD 785.15 million by 2030, registering a CAGR of 5.17% from 2022 to 2030." The company’s research suggests that the market for fluorescein angiography is projected to be driven by the rising prevalence of eye-related ailments and the rising elderly population. Macular degeneration is a leading cause of the age-related eye condition that leads in the loss of central and crisp vision.

It should also be noted that adverse effects of the procedures dye include nausea, vomiting, and hives. Some individuals may also suffer dry mouth, a metallic taste in the tongue, an increase in salivation (saliva overproduction), sneezing, or a rapid heartbeat. Research suggests these effects may slow the expansion of this procedures market.

Regional analysis of the global fluorescein angiography market

The market is split by region into North America, Europe, Asia-Pacific, and LAMEA.

In 2019, North America dominated the market for fluorescein angiography with a 48.8 percent share. This company reports that this is due to the high number of diabetic retinopathy patients and high volume of procedures. The number of Americans suffering from diabetic retinopathy is projected to increase from 7.7 million in 2010 to 14.6 million in 2050, according to the National Eye Institute (NIH). Therefore, fundus cameras are utilized to identify diabetic retinopathy at an early stage.

These fundus cameras are used to identify a variety of retinal disorders. In the introduction, advanced features in cameras such as hybrid cameras, digital devices, and portability, a rapidly growing geriatric population, and a high prevalence of chronic diseases such as diabetes are cited as factors expected to boost the fluorescein angiography market over the forecast period.

To review data in this report further, please visit https://straitsresearch.com/report/fluorescein-angiography-market.

Reference:
  1. Global fluorescein angiography market Size is Estimated to Reach USD 785.15 million by 2030, Growing at a CAGR of 5.17%: Straits Research. Straits Research. December 11, 2023. Accessed December 21, 2023. https://www.globenewswire.com/news-release/2023/12/11/2794005/0/en/Global-fluorescein-angiography-market-Size-is-Estimated-to-Reach-USD-785-15-million-by-2030-Growing-at-a-CAGR-of-5-17-Straits-Research.html
Recent Videos
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
© 2024 MJH Life Sciences

All rights reserved.